From August 26 to 28, 2025, the world-renowned Convention on Pharmaceutical Ingredients (CPHI) Korea 2025 was grandly held at the COEX Seoul Convention Center in South Korea. As a vital bridge connecting pharmaceutical enterprises to the global market, this year’s exhibition brought together pharmaceutical companies from across the world, serving as a platform to showcase innovation and collaboration in the global pharmaceutical industry.
Sichuan Xieli Pharmaceutical Co., Ltd., with the exhibition theme "Plant-Derived Technology, Shared Globally", stood out brilliantly at the event, demonstrating the outstanding strength of Chinese active pharmaceutical ingredient (API) enterprises to peers worldwide.
Exhibition Scene: Star Products and Authoritative Certifications
At the exhibition site, the booth of Xieli Pharma was thronged with visitors, becoming one of the focal points:
On the booth, featured APIs of plant extracts such as Berberine Hydrochloride and Rutin were neatly displayed, highlighting the core product advantages in the field of plant extraction;
International authoritative certification documents, including the European Pharmacopoeia (EP), Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP), and United States Pharmacopeia (USP), were exhibited on the display boards, strongly demonstrating Xieli’s pursuit of quality;
Professional pharmaceutical practitioners from around the world stopped to consult, engaging in in-depth exchanges on topics such as product characteristics, application scenarios, and cooperation models. The atmosphere was lively, and initial results were achieved.
Looking Back: Deepening Cooperation and Building Consensus
During the three-day exhibition, Xieli team took "deepening cooperation" as its core goal and carried out efficient connections with global partners:
In-depth discussions were held with long-term strategic partners from European, American, Asian and other countries. Both parties fully exchanged views on key issues such as product quality upgrading and supply chain optimization；
After multiple rounds of communication, the two sides reached a number of cooperation consensuses in areas like technical collaboration and market linkage, laying a solid foundation for future cooperation.
Looking Ahead: Exploring New Prospects and Empowering Growth
While consolidating existing cooperation, Xieli also seized the opportunity of the exhibition to make breakthrough progress in expanding into emerging markets:
Actively connected with potential customers in emerging markets, expanded and updated its customer cooperation network, and further widened its market coverage;
In line with current trends in the pharmaceutical market, discussed the R&D and production directions of current hot-selling products to align market demand with product layout;
The R&D, production, and sales departments collaborated closely and operated with high efficiency, jointly formulating a new round of full-industry-chain development plan covering product R&D, production, and end-market sales, which injected momentum into Xieli Pharma’s leapfrog development.
With the successful conclusion of CPHI Korea 2025, Xieli Pharmaceutical has once again proven the strength and development potential of Chinese API enterprises to the global market. Looking ahead, the company will continue to deepen its "specialization, internationalization, and branding" development strategy, take the CPHI global series of exhibitions as an important link, share the innovative achievements of plant extraction technology with global partners, and contribute more "Chinese wisdom" and "Chinese strength" to the cause of human health.
The end of the exhibition is not the end of cooperation, but the starting point for new opportunities. We sincerely invite global partners to continue following the development trend of Xieli and jointly explore the boundless possibilities of plant extracts in the field of pharmaceutical health.
